Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children
Purpura, Thrombocytopenic, Idiopathic
Recombinant Fusion Proteins
Retrospective analysis of off-study use of TPO agents in children with mainly chronic ITP showed increases in platelet counts in more than 4 of 5 children. The long-term use of TPO agents, up to 53 months, without tachyphylaxis supports their efficacy. These agents appear safe, effective, and tolerable in children with chronic ITP.